Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis.

about

Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis.

Item

http://www.wikidata.org/entity/Q41121490

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Lifetime effectiveness of mifa ...... Markov process model analysis.

@en

type

Item

label

Lifetime effectiveness of mifa ...... Markov process model analysis.

@en

prefLabel

Lifetime effectiveness of mifa ...... Markov process model analysis.

@en

P1476

Lifetime effectiveness of mifa ...... Markov process model analysis.

@en

P2093

Eui-Kyung Lee

http://www.w3.org/2001/XMLSchema#string

Hyun Jin Song

http://www.w3.org/2001/XMLSchema#string

Jun Ah Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.

Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Mifamurtide for the treatment of nonmetastatic osteosarcoma

Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.

Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma.

The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis.

P2888

s13277-015-3405-3

P304

6773-6779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-015-3405-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Euna Han

P577

2015-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001364951

http://www.w3.org/2001/XMLSchema#string

P698

25835978

http://www.w3.org/2001/XMLSchema#string